+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Pulmonary Drug Delivery Devices Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2022-2031

  • PDF Icon

    Report

  • 346 Pages
  • June 2022
  • Region: Global
  • Transparency Market Research
  • ID: 4852027
This report on the global pulmonary drug delivery devices market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2022 to 2031. The report provides revenue of the global pulmonary drug delivery devices market for the period 2017-2031, considering 2021 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global pulmonary drug delivery devices market from 2022 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the pulmonary drug delivery devices market.

Secondary research also Incuded Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global pulmonary drug delivery devices market.

The report Incudes an elaborate executive summary, along with a snapshot of the growth behavior of various segments Incuded in the scope of the study. Moreover, the report sheds light on the changing competitive dynamics in the global pulmonary drug delivery devices market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global pulmonary drug delivery devices market.

The report delves into the competitive landscape of the global pulmonary drug delivery devices market. Key players operating in the global pulmonary drug delivery devices market have been identified and each one of these has been profiled, in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are attributes of players in the global pulmonary drug delivery devices market profiled in this report.

Research Methodology:

The research methodology will be a combination of exhaustive primary and secondary research to analyze the market pulmonary drug delivery devices.

Secondary Research:

Secondary research Incudes a search of company literature, technical writing, patent data, Internet sources, and statistical data from government websites, trade associations, and agencies. This has proven to be the most reliable, effective, and successful approach for obtaining precise data, capturing industry participants’ insights, and recognizing business opportunities.

Secondary research sources that we typically refer, but are not limited to:

  • Company websites, presentations, annual reports, white papers, technical paper, product brochure
  • Internal and external proprietary databases and relevant patents
  • National government documents, statistical databases, and market reports
  • News articles, press releases, and webcasts specific to companies operating in the market

Specific Secondary Sources:

Industry Sources:

  • WorldWideScience.org
  • Elsevier, Inc
  • National Institutes of Health (NIH)
  • PubMed
  • NCBI
  • Department of Health Care Service

Trade Data Sources:

  • Trade Map
  • UN Comtrade
  • Trade Atlas

Company Information:

  • OneSource Business Browser
  • Hoover’s
  • Factiva
  • Bloomberg

Mergers & Acquisitions:

  • Thomson Mergers & Acquisitions
  • MergerStat
  • Profound

Primary Research:

During the course of research, we conduct in-depth interviews and discussions with a wide range of key industry participants and opinion leaders. Primary research represents bulk of research efforts, supplemented by extensive secondary research.

The publisher conducts primary interviews on the ongoing basis with industry participants and commentators to validate data and analysis.

A typical research interview fulfills the following functions:

  • Provides first-hand information on market size, market trends, growth trends, competitive landscape, outlook, etc
  • Helps in validating and strengthening secondary research findings
  • Further develops the analysis team’s expertise and market understanding
  • Primary research involves e-mail interactions, telephonic interviews, as well as face-to-face interviews for each market, category, segment, and sub-segment across geographies

Participants who typically take part in such a process Incude, but are not limited to:

  • Industry participants: Marketing/product managers, market intelligence managers, and regional sales managers
  • Purchasing/Sourcing managers, technical personnel, distributors
  • Outside experts: Investment bankers, valuation experts, and research analysts specializing in specific markets
  • Key opinion leaders specializing in different areas corresponding to different industry verticals

List of primary participants, but not limited to:

  • Advanced Oncotherapy PLC
  • Danfysik A/S
  • Hitachi, Ltd
  • IBA Worldwide
  • Mevion Medical Systems, Inc
Data Triangulation: Information culled from “Secondary & Primary Sources” is cross-checked with the publisher's 'Knowledge Repository', which is updated every quarter.

Market Estimation: Market size estimations involved in-depth study of product features, technology updates, geographic presence, product demand, sales data (value or volume), historical year-on-year growth, and others. Other approaches were also utilized to derive market size and forecasts. Where no hard data was available, we employed modeling techniques in order to produce comprehensive datasets.

A rigorous methodology has been adopted, wherein the available hard data are cross-referenced with the following data types to produce estimates:

  • Demographic Data: Healthcare expenditure, inflation rates, and others
  • Industry Indicators: R&D investment, technology stage, and infrastructure, sector growth, and facilities
Market Forecasting: Market forecasts for various segments are derived taking into account drivers, restraints/challenges, and opportunities prevailing in the market and considering advantages/disadvantages of segments/sub-segments over other segments/sub-segments. Business environment, historical sales pattern, unmet needs, competitive intensity, and country-wise surgery data are some of the other pivotal factors, which are considered to derive market forecasts.

Table of Contents

1. Preface
1.1. Report Scope
1.2. Market Segmentation
1.3. Research Highlights
2. Assumptions and Research Methodology
2.1. Assumptions
2.2. Research Methodology
3. Executive Summary
4. Market Overview
4.1. Product Type Overview
4.2. Key Industry Events
4.3. Market Opportunity Map
5. Market Dynamics
5.1. Drivers and Restraints Snapshot Analysis
5.2. Drivers
5.3. Restraints
5.4. Opportunity Analysis
5.5. Opportunities
5.6. Trends
5.7. Porter’s Five Forces Analysis
5.8. Value Chain Snapshot
6. Global Pulmonary Drugs Market Analysis, by Product Type
6.1. Key Findings
6.2. Introduction
6.3. Global Pulmonary Drug Delivery Devices Market Value Share Analysis, by Product Type
6.4. Global Pulmonary Drug Delivery Devices Market Forecast, by Product Type
6.4.1. Global Dry Powder Inhalers (DPIs) Market Revenue (US$ Mn) and Volume (Million Units), 2017-2031
6.4.2. Global Metered Dose Inhalers (MDIs) Market Revenue (US$ Mn) and Volume (Million Units), 2017-2031
6.4.3. Global Nebulizers Market Revenue (US$ Mn) and Volume (Million Units), 2017-2031
6.5. Global Pulmonary Drugs Market Attractiveness Analysis, by Product Type
6.6. Key Trends
7. Global Pulmonary Drug Delivery Devices Market Analysis, by Application
7.1. Key Findings
7.2. Introduction
7.3. Global Pulmonary Drug Delivery Devices Market Value Share Analysis, by Application, 2017 and 2031
7.4. Global Pulmonary Drug Delivery Devices Market Size (US$ Mn) and volume (Million Units) Forecast, by Application, 2017-2031
7.4.1. Global Asthma Market Revenue (US$ Mn) and volume (Million Units), 2017-2031
7.4.2. Global COPD Market Revenue (US$ Mn) and volume (Million Units), 2017-2031
7.4.3. Global Cystic Fibrosis Market Revenue (US$ Mn) and volume (Million Units), 2017-2031
7.4.4. Global Other Applications Market Revenue (US$ Mn) and volume (Million Units), 2017-2031
7.4.5. Global Pulmonary Drug Delivery Devices Market Attractiveness Analysis, by Application
7.5. Key Trends
8. Pulmonary Drug Delivery Devices Market Analysis, by Distribution Channel
8.1. Key Findings
8.2. Introduction
8.3. Global Pulmonary Drug Delivery Devices Market Value Share Analysis, by Distribution Channel, 2017 and 2031
8.4. Global Pulmonary Drug Delivery Devices Market Size (US$ Mn) and Volume (Million Units) Forecast, by Distribution Channel, 2017-2031
8.4.1. Global Retail Pharmacies Market Revenue (US$ Mn) and Volume (Million Units), 2017-2031
8.4.2. Global Hospital Pharmacies Market Revenue (US$ Mn) and Volume (Million Units), 2017-2031
8.4.3. Global E-commerce Market Revenue (US$ Mn) and Volume (Million Units), 2017-2031
8.5. Global Pulmonary Drug Delivery Devices Market Attractiveness Analysis, by Distribution Channel
9. Pulmonary Drug Delivery Devices Market Analysis, by Region
9.1. Global Scenario
9.2. Global Pulmonary Drug Delivery Devices Market Value Share Analysis By Region, 2017 and 2031
9.3. Global Pulmonary Drug Delivery Devices Market Size (US$ Mn) and Volume (Million Units) Forecast, by Region, 2017-2031
9.4. Global Pulmonary Drug Delivery Devices Market Attractiveness Analysis, by Region
10. North America Pulmonary Drug Delivery Devices Market Analysis
10.1. Key Findings
10.2. North America Pulmonary Drug Delivery Devices Market Size (US$ Mn) and Volume (Million Units) Forecast, 2017-2031
10.3. North America Pulmonary Drug Delivery Devices Market Size and Volume Y-o-Y Growth Projections, 2017-2031
10.4. North America Market Attractiveness Analysis, by Country, 2022-2031
10.5. North America Market Value Share Analysis, by Product Type, 2017 and 2031
10.6. North America Pulmonary Drug Delivery Devices Market Size (US$ Mn) and Volume (Million Units) Forecast, by Product Type, 2017-2031
10.7. North America Market Value Share Analysis, by Application, 2017 and 2031
10.8. North America Pulmonary Drug Delivery Devices Market Size (US$ Mn) and Volume (Million Units) Forecast, by Application, 2017-2031
10.9. North America Market Revenue Share Analysis, by Distribution Channel, 2017 and 2031
10.10. North America Pulmonary Drug Delivery Devices Market Size (US$ Mn) and Volume (Million Units) Forecast, by Distribution Channel, 2017-2031
10.11. North America Market Value Share Analysis, by Country, 2017 and 2031
10.12. North America Pulmonary Drug Delivery Devices Market Size (US$ Mn) and Volume (Million Units) Forecast, by Country, 2017-2031
10.13. North America Market Attractiveness Analysis, by Product Type, 2022-2031
10.14. North America Market Attractiveness Analysis, by Application, 2022-2031
10.15. North America Market Attractiveness Analysis, by Distribution Channel, 2022-2031
11. Europe Pulmonary Drug Delivery Devices Market Analysis
11.1. Key Findings
11.2. Europe Pulmonary Drug Delivery Devices Market Size (US$ Mn) and Volume (Million Units) Forecast, 2017-2031
11.3. Europe Pulmonary Drug Delivery Devices Market Size and Volume Y-o-Y Growth Projections, 2017-2031
11.4. Europe Market Attractiveness Analysis, by Country/Sub-region, 2022-2031
11.5. Europe Market Value Share Analysis, by Product Type, 2017 and 2031
11.6. Europe Pulmonary Drug Delivery Devices Market Size (US$ Mn) and Volume (Million Units) Forecast, by Product Type, 2017-2031
11.7. Europe Market Value Share Analysis, by Application, 2017 and 2031
11.8. Europe Pulmonary Drug Delivery Devices Market Size (US$ Mn) and Volume (Million Units) Forecast, by Application, 2017-2031
11.9. Europe Market Revenue Share Analysis, by Distribution Channel, 2017 and 2031
11.10. Europe Pulmonary Drug Delivery Devices Market Size (US$ Mn) and Volume (Million Units) Forecast, by Distribution Channel, 2017-2031
11.11. Europe Market Value Share Analysis, by Country/Sub-region, 2017 and 2031
11.12. Europe Pulmonary Drug Delivery Devices Market Size (US$ Mn) and Volume (Million Units) Forecast, by Country, 2017-2031
11.13. Europe Market Attractiveness Analysis, by Product Type, 2022-2031
11.14. Europe Market Attractiveness Analysis, by Application, 2022-2031
11.15. Europe Market Attractiveness Analysis, by Distribution Channel, 2022-2031
12. Asia Pacific Pulmonary Drug Delivery Devices Market Analysis
12.1. Key Findings
12.2. Asia Pacific Pulmonary Drug Delivery Devices Market Size (US$ Mn) and Volume (Million Units) Forecast, 2017-2031
12.3. Asia Pacific Pulmonary Drug Delivery Devices Market Size and Volume Y-o-Y Growth Projections, 2017-2031
12.4. Asia Pacific Market Attractiveness Analysis, by Country/Sub-region, 2022-2031
12.5. Asia Pacific Market Value Share Analysis, by Product Type, 2017 and 2031
12.6. Asia Pacific Pulmonary Drug Delivery Devices Market Size (US$ Mn) and Volume (Million Units) Forecast, by Product Type, 2017-2031
12.7. Asia Pacific Market Value Share Analysis, by Application, 2017 and 2031
12.8. Asia Pacific Pulmonary Drug Delivery Devices Market Size (US$ Mn) and Volume (Million Units) Forecast, by Application, 2017-2031
12.9. Asia Pacific Market Revenue Share Analysis, by Distribution Channel, 2017 and 2031
12.10. Asia Pacific Pulmonary Drug Delivery Devices Market Size (US$ Mn) and Volume (Million Units) Forecast, by Distribution Channel, 2017-2031
12.11. Asia Pacific Market Value Share Analysis, by Country/Sub-region, 2017 and 2031
12.12. Asia Pacific Pulmonary Drug Delivery Devices Market Size (US$ Mn) and Volume (Million Units) Forecast, by Country, 2017-2031
12.13. Asia Pacific Market Attractiveness Analysis, by Product Type, 2022-2031
12.14. Asia Pacific Market Attractiveness Analysis, by Application, 2022-2031
12.15. Asia Pacific Market Attractiveness Analysis, by Distribution Channel, 2022-2031
13. Latin America Pulmonary Drug Delivery Devices Market Analysis
13.1. Key Findings
13.2. Latin America Pulmonary Drug Delivery Devices Market Size (US$ Mn) and Volume (Million Units) Forecast, 2017-2031
13.3. Latin America Pulmonary Drug Delivery Devices Market Size and Volume Y-o-Y Growth Projections, 2017-2031
13.4. Latin America Market Attractiveness Analysis, by Country/Sub-region, 2022-2031
13.5. Latin America Market Value Share Analysis, by Product Type, 2017 and 2031
13.6. Latin America Pulmonary Drug Delivery Devices Market Size (US$ Mn) and Volume (Million Units) Forecast, by Product Type, 2017-2031
13.7. Latin America Market Value Share Analysis, by Application, 2017 and 2031
13.8. Latin America Pulmonary Drug Delivery Devices Market Size (US$ Mn) and Volume (Million Units) Forecast, by Application, 2017-2031
13.9. Latin America Market Revenue Share Analysis, by Distribution Channel, 2017 and 2031
13.10. Latin America Pulmonary Drug Delivery Devices Market Size (US$ Mn) and Volume (Million Units) Forecast, by Distribution Channel, 2017-2031
13.11. Latin America Market Value Share Analysis, by Country/Sub-region, 2017 and 2031
13.12. Latin America Pulmonary Drug Delivery Devices Market Size (US$ Mn) and Volume (Million Units) Forecast, by Country, 2017-2031
13.13. Latin America Market Attractiveness Analysis, by Product Type, 2022-2031
13.14. Latin America Market Attractiveness Analysis, by Application, 2022-2031
13.15. Latin America Market Attractiveness Analysis, by Distribution Channel, 2022-2031
14. Middle East & Africa Pulmonary Drug Delivery Devices Market Analysis
14.1. Key Findings
14.2. Middle East & Africa Pulmonary Drug Delivery Devices Market Size (US$ Mn) and Volume (Million Units) Forecast, 2017-2031
14.3. Middle East & Africa Pulmonary Drug Delivery Devices Market Size and Volume Y-o-Y Growth Projections, 2017-2031
14.4. Middle East & Africa Market Attractiveness Analysis, by Country/Sub-region, 2022-2031
14.5. Middle East & Africa Market Value Share Analysis, by Product Type, 2017 and 2031
14.6. Middle East & Africa Pulmonary Drug Delivery Devices Market Size (US$ Mn) and Volume (Million Units) Forecast, by Product Type, 2017-2031
14.7. Middle East & Africa Market Value Share Analysis, by Application, 2017 and 2031
14.8. Middle East & Africa Pulmonary Drug Delivery Devices Market Size (US$ Mn) and Volume (Million Units) Forecast, by Application, 2017-2031
14.9. Middle East & Africa Market Revenue Share Analysis, by Distribution Channel, 2017 and 2031
14.10. Middle East & Africa Pulmonary Drug Delivery Devices Market Size (US$ Mn) and Volume (Million Units) Forecast, by Distribution Channel, 2017-2031
14.11. Middle East & Africa Market Value Share Analysis, by Country/Sub-region, 2017 and 2031
14.12. Middle East & Africa Pulmonary Drug Delivery Devices Market Size (US$ Mn) and Volume (Million Units) Forecast, by Country/Sub-region, 2017-2031
14.13. Middle East & Africa Market Attractiveness Analysis, by Product Type, 2022-2031
14.14. Middle East & Africa Market Attractiveness Analysis, by Application, 2022-2031
14.15. Middle East & Africa Market Attractiveness Analysis, by Distribution Channel, 2022-2031
15. Competition Landscape
15.1. Global Pulmonary Drugs Market Share Analysis, by Company, 2015
15.2. Competitive Dashboard
15.3. Pipeline Snapshot
16. Company Profiles
16.1. Boehringer Ingelheim GmbH
16.1.1. Company Overview
16.1.2. Business Overview
16.1.3. Financial Overview
16.1.4. SWOT Analysis
16.1.5. Strategic Overview
16.2. Novartis AG
16.2.1. Company Overview
16.2.2. Business Overview
16.2.3. Financial Overview
16.2.4. SWOT Analysis
16.2.5. Strategic Overview
16.3. GlaxoSmithKline plc
16.3.1. Company Overview
16.3.2. Business Overview
16.3.3. Financial Overview
16.3.4. SWOT Analysis
16.3.5. Strategic Overview
16.4. AstraZeneca plc
16.4.1. Company Overview
16.4.2. Business Overview
16.4.3. Financial Overview
16.4.4. SWOT Analysis
16.4.5. Strategic Overview
16.5. Teva Pharmaceutical Industries Ltd.
16.5.1. Company Overview
16.5.2. Business Overview
16.5.3. Financial Overview
16.5.4. SWOT Analysis
16.5.5. Strategic Overview
16.6. Merck & Co., Inc.
16.6.1. Company Overview
16.6.2. Business Overview
16.6.3. Financial Overview
16.6.4. SWOT Analysis
16.6.5. Strategic Overview
16.7. MannKind Corporation
16.7.1. Company Overview
16.7.2. Business Overview
16.7.3. Financial Overview
16.7.4. SWOT Analysis
16.7.5. Strategic Overview
16.8. F. Hoffmann-La Roche Ltd.
16.8.1. Company Overview
16.8.2. Business Overview
16.8.3. Financial Overview
16.8.4. SWOT Analysis
16.8.5. Strategic Overview
16.9. Bristol-Myers Squibb Company
16.9.1. Company Overview
16.9.2. Business Overview
16.9.3. Financial Overview
16.9.4. SWOT Analysis
16.9.5. Strategic Overview
16.10. Mylan N.V.
16.10.1. Company Overview
16.10.2. Business Overview
16.10.3. Financial Overview
16.10.4. SWOT Analysis
16.10.5. Strategic Overview
16.11. Omron Corporation
16.11.1. Company Overview
16.11.2. Business Overview
16.11.3. Financial Overview
16.11.4. SWOT Analysis
16.11.5. Strategic Overview
16.12. 3M Healthcare
16.12.1. Company Overview
16.12.2. Business Overview
16.12.3. Financial Overview
16.12.4. SWOT Analysis
16.12.5. Strategic Overview
16.13. Sunovion Pharmaceuticals, Inc.
16.13.1. Company Overview
16.13.2. Business Overview
16.13.3. Financial Overview
16.13.4. SWOT Analysis
16.13.5. Strategic Overview
16.14. Koninklijke Philips N.V.
16.14.1. Company Overview
16.14.2. Business Overview
16.14.3. Financial Overview
16.14.4. SWOT Analysis
16.14.5. Strategic Overview
16.15. Gerresheimer AG
16.15.1. Company Overview
16.15.2. Business Overview
16.15.3. Financial Overview
16.15.4. SWOT Analysis
16.15.5. Strategic Overview
16.16. Bespak
16.16.1. Company Overview
16.16.2. Business Overview
16.16.3. Financial Overview
16.16.4. SWOT Analysis
16.16.5. Strategic Overview
16.17. AptarGroup, Inc.
16.17.1. Company Overview
16.17.2. Business Overview
16.17.3. Financial Overview
16.17.4. SWOT Analysis
16.17.5. Strategic Overview
16.18. SHL Group
16.18.1. Company Overview
16.18.2. Business Overview
16.18.3. SWOT Analysis
16.18.4. Strategic Overview
16.19. Nypro Healthcare Inc. (Jabil Circuit Inc.)
16.19.1. Company Overview
16.19.2. Business Overview
16.19.3. Financial Overview
16.19.4. SWOT Analysis
16.19.5. Strategic Overview
16.20. Hovione
16.20.1. Company Overview
16.20.2. Business Overview
16.20.3. Financial Overview
16.20.4. SWOT Analysis
16.20.5. Strategic Overview
16.21. Chiesi Farmaceutici S.p.A.
16.21.1. Company Overview
16.21.2. Business Overview
16.21.3. Financial Overview
16.21.4. SWOT Analysis
16.21.5. Strategic Overview

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Boehringer Ingelheim GmbH
  • Novartis AG
  • GlaxoSmithKline plc
  • Teva Pharmaceutical Industries Ltd.
  • AstraZeneca plc
  • Merck & Co., Inc.
  • MannKind Corporation
  • F. Hoffmann-La Roche Ltd.
  • Bristol-Myers Squibb Company
  • Mylan N.V.
  • Omron Corporation
  • 3M Healthcare
  • Sunovion Pharmaceuticals, Inc.
  • Koninklijke Philips N.V.
  • Gerresheimer AG
  • Bespak
  • AptarGroup, Inc.
  • SHL Group
  • Nypro Healthcare Inc. (Jabil Circuit Inc.)
  • Hovione
  • Chiesi Farmaceutici S.p.A.